Brexit spurs SPC litigation doubt for pharma companies
Pharma businesses say they are uncertain of whether decisions around Article 3a of the EU’s SPC Regulation would be followed in the UK for very long after Brexit – and that divergence might further complicate their litigation strategies.
Ericsson, Benevolent AI and a bank say that open-source software is a valuable resource for driving innovation, but that businesses using it must have the right controls to ensure that they don’t carelessly take a restrictive licence that renders their patent estates worthless.
Sign up to receive more content like this in Patent Strategy’s weekly newsletter.
The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.
© 2021 Euromoney Institutional Investor PLC. For help please see our FAQs.